Your browser doesn't support javascript.
loading
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A; Pickard, Michael D; Sandor, Victor; Robert, Caroline; Flaherty, Keith T.
Afiliação
  • Dummer R; Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch.
  • Ascierto PA; Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
  • Gogas HJ; Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece.
  • Arance A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Mandala M; Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.
  • Liszkay G; Department of Dermatology, National Institute of Oncology, Budapest, Hungary.
  • Garbe C; Department of Dermatology, University Hospital Tüebingen, Tüebingen, Germany.
  • Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
  • Krajsova I; Department of Dermato-oncology, University Hospital Prague, Charles University First Medical Faculty, Prague, Czech Republic.
  • Gutzmer R; Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
  • Chiarion-Sileni V; Melanoma Cancer Unit, Oncology Institute of Veneto IRCCS, Padua, Italy.
  • Dutriaux C; Department of Oncologic Dermatology, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France.
  • de Groot JWB; Department of Medical Oncology, Isala, Zwolle, Netherlands.
  • Yamazaki N; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Loquai C; Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
  • Moutouh-de Parseval LA; Translational Clinical Oncology, Novartis Pharma AG, Basel, Switzerland.
  • Pickard MD; Array BioPharma, Boulder, CO, USA.
  • Sandor V; Array BioPharma, Boulder, CO, USA.
  • Robert C; Service of Dermatology, Department of Medicine, Paris-Sud University, Gustave Roussy, Villejuif, France.
  • Flaherty KT; Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
Lancet Oncol ; 19(5): 603-615, 2018 05.
Article em En | MEDLINE | ID: mdl-29573941
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Sulfonamidas / Benzimidazóis / Carbamatos / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Vemurafenib / Melanoma Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Sulfonamidas / Benzimidazóis / Carbamatos / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Vemurafenib / Melanoma Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article